Open Access Journal

Journal of Cancer Science and Clinical Oncology

ISSN: 2394-6520 IF: 3.4* DOI: 10.15744

Email: jcs@annexpublishers.com

Submit Manuscript → Browse Articles Instructions for Authors

Journal at a Glance

Review typeDouble-blind

Target decision~21 days

Submission feeNone

LicenceCC BY 4.0

Word limitsNone

About

About the Journal

Journal of Cancer science and Clinical Oncology (JCSCO) is a peer reviewed open access, scholarly journal that aims publishes original research articles, review articles, case reports, short communications, etc. in all areas of cancer science and to act as a platform for clinicians and academicians to collaborate and share their knowledge.

Why publish with us

Built for researchers

⚡

Fast peer review

Target first decision within 21 days. Double-blind review by 2-3 field experts.

🔓

Fully open access

All articles CC BY 4.0. No paywalls. Compliant with funder mandates worldwide.

🔗

DOI & indexing

Every article receives a unique DOI. Indexed in PubMed, Google Scholar, CrossRef.

🚀

Rapid publication

Published within 7 days of acceptance. No unnecessary delays in dissemination.

🌐

Global & equitable

Readers in 170+ countries. Waiver program available for authors from developing nations.

📈

No content limits

No word limits. Multiple article formats: research, reviews, case reports, short communications.

Now accepting submissions

Journal of Cancer Science and Clinical Oncology

Submit your original research, reviews, and case reports. No submission fees. Double-blind peer review within 21 days.

Submit now → Author guidelines

How it works

Simple. Transparent. Streamlined.

Submit

Upload your manuscript via our online portal. Quality check within 48 hours.

Review

Double-blind peer review by 2-3 field experts. Target decision: ~21 days.

Revise

Constructive feedback from reviewers. Dedicated editorial support throughout.

Publish

Published within 7 days. DOI assigned via CrossRef. Globally indexed.

Submit Manuscript →

Highlights

Research Highlights

Diagnosis of Lung Cancer by Fractal Analysis of Damaged DNA

Cancer starts when cells in a part of the body start to grow out of control. In fact cells become cancer cells because of DNA damage.

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit.

Surgery for lymph node metastases of medullary thyroid carcinoma: A review

Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy of the thyroid C cells that occurs in hereditary and sporadic clinical settings.

An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer

The study is to investigate a Hybrid IMRT/VMAT technique which combines intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for the treatment of nonsmall cell lung cancer (NSCLC).